Results 181 to 190 of about 285,474 (314)

Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 16-26, January 2026.
Abstract Chronic kidney disease (CKD) is a serious complication occurring in nearly one of three people with type 1 diabetes (T1D). Major therapeutic advances have been made in the management of CKD for people with type 2 diabetes (T2D), thereby improving their kidney, cardiovascular, and survival outcomes.
Katherine R. Tuttle, Linong Ji, Chantal Mathieu, Jonathan Rosen   +3 more
wiley   +1 more source

Maximizing the Therapeutic Effect of Endothelin Receptor Antagonists in Pulmonary Fibrosis: A Paradigm for Treating the Disease. [PDF]

Int J Mol Sci
Cantor J.
europepmc   +1 more source

The SONAR study-is there a future for endothelin receptor antagonists in diabetic kidney disease? [PDF]

Ann Transl Med, 2019
Cahn A, Cernea S, Raz I.
europepmc   +1 more source

Immunotherapy and endothelin receptor antagonists for treatment of castration‐resistant prostate cancer

International Journal of Cancer, 2013
N. Shao*, Yang Wang, W. Jiang, D. Qiao, Shi-ge Zhang, Ye Wu, Xiang Xiang Zhang, Jiufeng Wang, Yi Ding, N. Feng   +9 more
semanticscholar   +1 more source

Neuroprotection afforded by antagonists of endothelin-1 receptors in experimental stroke

, 2012
Octavio Moldes, Tomás Sobrino, Miguel Blanco, Jesús Agulla, David Barral, Pedro Ramos‐Cabrer, José Castillo   +6 more
openalex   +2 more sources

A matter arising: When should inflammatory and autoimmune rheumatic diseases be considered ‘early’?

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
Timely recognition of inflammatory and autoimmune rheumatic diseases (IARDs) is important to optimize the early diagnosis with tailored interventions and possible prevention of irreversible organ damage. This narrative review provides an update by summarizing the advances in identifying the early stages of rheumatoid arthritis, systemic sclerosis and ...
Elvis Hysa, Emanuele Gotelli, Carmen Pizzorni, Sabrina Paolino, Alberto Sulli, Vanessa Smith, Rosanna Campitiello, Maurizio Cutolo   +7 more
wiley   +1 more source

Integrated Network Pharmacology, Single‐Cell Transcriptomics Unveil the Mechanistic Role of Morusin in Aortic Dissection

Journal of Cellular and Molecular Medicine, Volume 30, Issue 1, January 2026.
ABSTRACT Aortic dissection is a life‐threatening cardiovascular emergency with limited pharmacological options. This study focuses on elucidating the multi‐target and multi‐pathway mechanisms through which morusin mitigates aortic dissection progression, integrating network pharmacology, single‐cell transcriptomics and experimental validation.
Zhaomeng Wang, Haoran Zhang, Zhanxiong Xie, Yukun Xiang, Yiwen Fu, Zixun Wang, Haiqing Jiao, Nan Lin, Chenguang Niu, Chao Jiang, Lemin Zheng   +10 more
wiley   +1 more source

Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data. [PDF]

Ther Adv Respir Dis
Dong S, Guo X, Wang H, Sun C.
europepmc   +1 more source

Tale of 2 Endothelin Receptor Antagonists in Eisenmenger Syndrome. [PDF]

Circulation, 2019
Ivy D, Wilson N.
europepmc   +1 more source

Current Status of Research on Losartan in Tumour Therapy

Journal of Cellular and Molecular Medicine, Volume 30, Issue 1, January 2026.
ABSTRACT Losartan, a widely prescribed antihypertensive agent, has attracted growing interest as a potential adjuvant in cancer therapy due to its affordability, established safety profile and pleiotropic effects. Emerging preclinical evidence demonstrates that losartan can effectively modulate the tumour microenvironment (TME) by inhibiting ...
Han Wang, Shuang Yuan, Hongjing Wang
wiley   +1 more source